Key facts
- AutoIVF’s last known valuation is $31.0M (May 2025).
- It has raised $8.5M across 3 recorded rounds; the latest was Early Stage VC ($5.0M) in May 2025.
- Notable investors include National Institutes of Health, Alpha Edison, ABI LAB, Coriolis Ventures, U.S. Department of Health and Human Services — 6 tracked in total.
- AutoIVF has filed 3 Form Ds with the SEC since 2020, most recently May 2025 ($5.0M sold to 24 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for AutoIVF
Funding rounds
3 roundsAbout AutoIVF
Operator of a biotechnology company intended to reduce cost and increase accessibility by transforming IVF through automation. The company specializes in transforming in vitro fertilization by automating central procedures that are costly and time-consuming, which will increase reliability and accessibility to infertility, enabling patients to conceive a newborn with advanced medical procedures.
- Sector
- Healthcare
- HQ
- Natick, MA, United States
- Founded
- 2019
- Employees
- 10
- Website
- autoivf.com/
- Ownership
- Privately Held (backing)
AutoIVF doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AutoIVF shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AutoIVF in its N-PORT filings yet. We sweep new filings monthly.